Detail of "73989-17-0"

Reference

The in vitro activity of various anthelmintic compounds against Haemonchus contortus larvae

The in vitro activity of various anthelmintic compounds against Haemonchus contortus larvae.Some chemicals with cas registry numbers like 14769-73-4 and 7181-73-9 are also used. Boisvenue, R. J.; Brandt, M. C.; Galloway, R. B.; Hendrix, J. C. (Parasitol. Dep., Eli Lilly and Co., Greenfield, IN 46140, USA). Vet. Parasitol., 13(4), 341-7 (English) 1983. CODEN: VPARDI. ISSN: 0304-4017. DOCUMENT TYPE: Journal CA Section: 5 (Agrochemical Bioregulators) Twenty-five known anthelmintic compds. were evaluated in vitro against the highly motile exsheathed nonfeeding 3rd-stage of H. contortus larvae. Activity was based on lack of motility or death of larvae after 24 h of chem. exposure. Six compds. (avermectin [73989-17-0], closantel [57808-65-8], levamisole [14769-73-4], morantel [20574-50-9], phenylhydrazine [100-63-0], and ticarbodine [31932-09-9]) were active at a concn. of ￡100 mg/cm3. The most active compds. were avermectin and levamisole. When higher in vitro concns. were used, 10 compds. (bephenium [7181-73-9], coumaphos [56-72-4], dichlorovos [62-73-7], disophenol [305-85-1], hygromycin b [31282-04-9], methyridine [114-91-0], parbendazole [14255-87-9], phenothiazine [92-84-2], pyrantel [15686-83-6], and thiabendazole [148-79-8]) exhibited activity. Nine compds. were inactive; among these were the new benzimidazoles, i.e., albendazole, fenbendazole, mebendazole, and oxibendazole. Because of the inactivity of the new benzimidazoles, this in vitro system is unsuitable as a routine screening tool. Also, the system favors drugs that act quickly through percuticular entry. In an initial group of 5280 untested compds., 254 (4.8%) exhibited in vitro activity at 100 mg/cm3 against the nonfeeding larvae stage. The exogenous and in vitro cultivation techniques required for collecting, cleaning and exsheathing the larvae are described. .

Recombinant DNA cloning vector pVE1, deletion and hybrid mutants, and recombinant derivatives thereof, products and processes

Recombinant DNA cloning vector pVE1, deletion and hybrid mutants, and recombinant derivatives thereof, products and processes. Macneil, Tanya; Gibbons, Patrice H. (Merck and Co., Inc. , USA). Eur. Pat. Appl. EP 118367 A2 12 Sep 1984, 43 pp. DESIGNATED STATES: R: CH, DE, FR, GB, IT, LI, NL. (English). (European Patent Organization). CODEN: EPXXDW. CLASS: IC: C12N015-00; C12N001-20. ICA: C12P021-00; C12P001-06. ICI: C12N001-20, C12R001-465. APPLICATION: EP 84-400446 6 Mar 1984. PRIORITY: US 83-473181 8 Mar 1983. DOCUMENT TYPE: Patent CA Section: 3 (Biochemical Genetics) Section cross-reference(s): 16 The high copy no., self-transmissible, small plasmid vector pVE1 is isolated from Streptomyces and used in the construction of recombinant and deletion deriv. plasmid vectors for cloning in Streptomyces avermitilis and other Streptomyces species. Thus, the BclI fragment of a cloned thiostrepton [1393-48-2] gene (tsr) was inserted into the BglII site at 6.15 kilobases on plasmid pVE1 which had been isolated from mycelia of S. venezuelae or S. linidans by conventional methods. The deletion deriv. plasmid obtained, pVE28, was further modified by inserting the gene for avermectin [73989-17-0] at the BglII site; pVE28 was then used to transform mutant S. avermitilis blocked in avermectin formation. Thiostrepton-resistant clones were than screened by HPLC to identify those contg. the wild-type avermectin gene for use in high-yield anermectin prodn. Plasmid pVE1 or its derivs. were also used successfully in cloning hepatitis B surface antigen and neomycin [1404-04-2]-resistance genes in Streptomyces.